InnoCare Pharma Limited

InnoCare Pharma Limited is a commercial-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative drugs for the treatment of cancer and autoimmune diseases. Headquartered in Beijing, China, the company operates with a mission to utilize cutting-edge science and technology to provide patients with new medicines and improve public health. Its philosophy, "Science Drives Innovation for the Benefit of Patients," guides its efforts to address significant unmet medical needs globally.

The company has established an integrated biopharmaceutical platform encompassing drug discovery, clinical development, manufacturing, and commercialization capabilities. Key commercialized products include Orelabrutinib, a Bruton's tyrosine kinase (BTK) inhibitor for hematologic malignancies and autoimmune diseases; Tafasitamab, an anti-CD19 monoclonal antibody for diffuse large B-cell lymphoma (DLBCL); and Zurletrectinib, a pan-TRK inhibitor for NTRK fusion-positive cancers. InnoCare's robust pipeline also features drug candidates like ICP-332 and ICP-488 (TYK2 inhibitors for autoimmune diseases), Mesutoclax (a BCL2 inhibitor), and ICP-189 (an SHP2 inhibitor), among others, targeting a diverse range of indications.

Led by Co-founder, Chairwoman, and CEO Dr. Jasmine Cui, InnoCare Pharma maintains a strong market position with a dual listing on the Hong Kong Stock Exchange (HKEX) and the Shanghai Stock Exchange (SSE). Recent notable developments include the acceptance of a New Drug Application (NDA) for Orelabrutinib in primary immune thrombocytopenia (ITP) in China in May 2026, and its approval in Australia. The company reported strong revenue growth and profitability in Q1 2026, driven by the commercial success of its approved drugs and strategic global business development initiatives.